X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FE-203799 (apraglutide) is a once-weekly , a next-generation, long-acting glucagon-like peptide-2 (GLP-2) analog. It is being evaluated for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: FE-203799
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
FE-203799 (apraglutide) is an investigational, next-generation, long-acting synthetic GLP-2 analog. It is being evaluated for the treatment of short bowel syndrome with intestinal failure.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE-203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: VectivBio
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition December 12, 2023
Details:
Linzess (linaclotide) is the first and only FDA-approved prescription therapy for irritable bowel syndrome with constipation and chronic idiopathic constipation (CIC) in adults and functional constipation (FC) in children and adolescents 6 to 17 years of age.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Recipient: VectivBio
Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition May 22, 2023
Details:
Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Lead Product(s): Apraglutide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Asahi Kasei Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Linzess (linaclotide) is a guanylate cyclase-C (GC-C) agonist. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. It is being developed for IBS-C or CIC.
Lead Product(s): Linaclotide
Therapeutic Area: Gastroenterology Product Name: Linzess
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
FE203799 (apraglutide) is an investigational new drug that is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and working capital.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 18, 2022
Details:
VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and working capital.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
